Results 1 to 10 of about 4,821 (183)
Molecular Metabolism, 2021 Background: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and ...
Nina Sonne +2 more
doaj +5 more sources
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile [PDF]
BMC Endocrine Disorders, 2021 Background Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard.
Anna Thorsø Larsen +4 more
doaj +3 more sources
Biomedicines, 2022 Background: Dual Amylin and Calcitonin Receptor Agonists (DACRAs) are treatment candidates for obesity and type 2 diabetes. Recently, a once-weekly DACRA (KBP-A) showed promise, potentially due to its different exposure profile compared to daily DACRA ...
Nina Sonne +3 more
doaj +3 more sources
Dual Amylin and Calcitonin Receptor Agonists: A Novel Treatment for Obesity and Related Co-Morbidities [PDF]
, 2017 Fedme og de associerede livsstilssygdomme, såsom type 2 diabetes (T2D), non-alkoholisk steatohepatitis (NASH), hjerte-karsygdomme og kræft er konsekvenser af den moderne stillesiddende livsstil. Behandlingen af fedme er begrænset til livsstilsinterventioner. I alvorlige tilfælde kan fedmekirurgi og nogle få farmakoterapier dog benyttes.
Gydesen, Sofie
core +2 more sources
Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats [PDF]
American Journal of Physiology-Endocrinology and Metabolism, 2023 These studies describe the beneficial effects of using a dual amylin and calcitonin receptor agonist (DACRA) for diabetes-related kidney complications. DACRA treatment reduced levels of serological biomarkers associated with kidney fibrosis. These reductions were further reflected by reduced collagen expression in diabetic kidneys.
Simone Anna Melander +7 more
openaire +3 more sources
The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy [PDF]
The Journal of Pharmacology and Experimental Therapeutics, 2019 KBP-088 (KeyBiosciencePeptide 088) is a potent dual amylin and calcitonin receptor agonist (DACRA). DACRAs are known to elicit potent activity in terms of typical amylin-induced responses, such as reducing food intake and body weight. However, to what extent amylin infusion can mimic the effects of the dual agonist KBP-088 is unknown.
Anna Thorsø, Larsen +5 more
openaire +5 more sources
History of current non-insulin medications for diabetes mellitus [PDF]
Journal of Community Hospital Internal Medicine Perspectives, 2012 This article is a brief review of the current non-insulin agents for diabetes mellitus in the United States, namely, sulfonylureas, biguanides, thiazolidinediones, meglitinides, α-glucosidase inhibitors, glucacon-like peptide-1 receptor agonists ...
Celeste C. L. Quianzon, Issam E. Cheikh
doaj +1 more source
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Molecular Metabolism, 2021 Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre ...
Laurie L. Baggio, Daniel J. Drucker
doaj +1 more source
Biomolecules, 2021 The calcitonin and amylin receptors (CTR and AMY receptors) are the drug targets for osteoporosis and diabetes treatment, respectively. Salmon calcitonin (sCT) and pramlintide were developed as peptide drugs that activate these receptors.
Sangmin Lee
doaj +1 more source
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
Frontiers in Endocrinology, 2021 The hormones amylin and calcitonin interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts.
David S. Mathiesen +10 more
doaj +1 more source